<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ru">
	<id>http://wikikurgan.ru/index.php?action=history&amp;feed=atom&amp;title=Top_5_Estimates_Upon_MS-275_This_Season</id>
	<title>Top 5 Estimates Upon MS-275 This Season - История изменений</title>
	<link rel="self" type="application/atom+xml" href="http://wikikurgan.ru/index.php?action=history&amp;feed=atom&amp;title=Top_5_Estimates_Upon_MS-275_This_Season"/>
	<link rel="alternate" type="text/html" href="http://wikikurgan.ru/index.php?title=Top_5_Estimates_Upon_MS-275_This_Season&amp;action=history"/>
	<updated>2026-11-18T08:06:38Z</updated>
	<subtitle>История изменений этой страницы в вики</subtitle>
	<generator>MediaWiki 1.31.8</generator>
	<entry>
		<id>http://wikikurgan.ru/index.php?title=Top_5_Estimates_Upon_MS-275_This_Season&amp;diff=2154377&amp;oldid=prev</id>
		<title>Sampanoffice1: Новая страница: «CRP levels in females remained unaltered for the first 3 mo, irrespective of effective PAP treatment, while on the contrary males presented a significant fall in …»</title>
		<link rel="alternate" type="text/html" href="http://wikikurgan.ru/index.php?title=Top_5_Estimates_Upon_MS-275_This_Season&amp;diff=2154377&amp;oldid=prev"/>
		<updated>2017-02-17T03:29:50Z</updated>

		<summary type="html">&lt;p&gt;Новая страница: «CRP levels in females remained unaltered for the first 3 mo, irrespective of effective PAP treatment, while on the contrary males presented a significant fall in …»&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Новая страница&lt;/b&gt;&lt;/p&gt;&lt;div&gt;CRP levels in females remained unaltered for the first 3 mo, irrespective of effective PAP treatment, while on the contrary males presented a significant fall in CRP over that period. At 6-mo, a significant decrease was observed in all patients who used PAP, while CRP values approached those of subjects without OSAS. A recent meta-analysis on the influence of PAP therapy on CRP levels in OSAS concluded that at least 3 mo of treatment is required to significantly decrease levels indicating that the inflammatory process is still active through this period[75]. CRP levels further declined after 6 mo of PAP treatment. Furthermore, Xie et al[76] also [https://en.wikipedia.org/wiki/Quinapyramine Quinapyramine] showed a significant decrease on CRP levels, with better benefits with therapy duration of �� 3 mo and more adequate compliance (�� 4 h/night). A previous meta-analysis [http://www.selleckchem.com/products/MS-275.html MS-275 order] showed PAP therapy to significantly reduce CRP levels, by 0.11 mg/dL, or 17.8%[77]. In another study[65] we observed that the division of the patients into a good and a poor PAP compliance group affected CRP evolution, with the good PAP compliance group to show exclusively a statistically significant decrease after 6 mo therapy. Although CRP levels were decreased in the poor compliance group, only a statistically significant trend was observed after 1 year of treatment. Based on that, assuming that PAP use is not adequate according to the generally accepted criteria (use [http://www.selleckchem.com/products/GDC-0449.html this website] effect of any reduction. CRP is only one element of the underlying noxius inflammatory process in OSAS. However, there is a shortage of simple, standardized, and cost-effective methods for patient follow-up, and CRP presents these features. In this way, CRP might be valuable along with all other parameters used for the follow-up of patients with OSAS in PAP clinics. Further research is required to define those OSAS patients who will have a considerable reduction with treatment, as well as to understand the significance of the interaction between cardiovascular risk factor and CRP reduction in patients with OSAS.&lt;/div&gt;</summary>
		<author><name>Sampanoffice1</name></author>
		
	</entry>
</feed>